Rochester, NY 7/10/2009 10:52:53 PM
Stock Exchange News - CTIC - CTIC Completes the submission for Pixantrone and ask for Priority Review - Sourced WhisperFromWallStreet.com
Cell Therapeutics, Inc.
Stock Exchange News - CTIC - CTIC Completes the submission for Pixantrone and ask for Priority Review - Sourced WhisperFromWallStreet.com
COMPANY - Cell Therapeutics, Inc.,CTIC
NEWS - Cell Therapeutics, Inc.announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis."This is a major milestone for CTI and is the cornerstone of a turnaround strategy for us in meeting our goals of becoming a profitable operating business," said James A. Bianco, M.D., Chief Executive Officer of CTI.
Last Trade: 1.37
Day's Range: 1.36 - 1.40
52wk Range: 0.05 - 4.70
Volume: 3,271,324
ABOUT - Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin?s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
---
WhisperFromWallStreet is a news letter focusing on sending specific alerts to our subscribers. These alerts represent which stocks we believe are going to run. Additionally we spend time teaching how to become a better trader. If you like more information or to Sign Up for free alerts, visit us at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT INFORMATION: Nothing in this press release should be interpreted as a solicitation to buy any stock or security represented herein. WhisperfromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers. Information presented here is based on our opinion only.
